The Online Investor
GILD Buyback image

Gilead Sciences, Inc. Buyback

OLI recorded this information on 2/3/2015

Company: Gilead Sciences, Inc.
Buyback: GILD buyback
$Amount Authorized: $15,000,000,000
Buyback Details: The Board of Directors also approved the repurchase of up to an additional $15.0 billion of the company's common stock. This new program is in addition to the currently authorized three-year $5.0 billion repurchase program (authorized in May 2014). As of December 31, 2014, approximately $3 billion remained in the May 2014 program. The new program will expire 5 years after the completion of the May 2014 program. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Gilead's management and in accordance with the requirements of the Securities and Exchange Commission.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Gilead Sciences SEC Filing Email Alerts Service

Open the GILD Page at The Online Investor »

Company Name: 
Gilead Sciences Inc
Stock buyback: 
GILD buyback
Number of ETFs Holding GILD: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the GILD Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree GILD Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.65 out of 4)
2nd percentile
(ranked lower than approx. 98% of all stocks covered)

Analysts' Target Price:
GILD Stock Forecast

Based on Zacks ABR data;
powered by Xignite

GILD Buyback Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.